CD274 and neoplasm: In fact, Atezolizumab (an anti PDL-1 antibody) and Pembrolizumab (Anti PD-1 antibody) have been successfully used in TNBC, improving overall survival but only in the subgroup of tumors expressing high levels of programmed cell death ligand 1 (PD-L1–stained tumor-infiltrating immune cells of any intensity covering ≥1% of the tumor area), as determined by a U.S. Food and Drug Administration (FDA)-approved test (4), and pCR in the neoadjuvant setting; respectively (5).